Human Parainfluenza Virus 3 (HPIV-3) Infection Drug Development Pipeline Study, H2 2018

August 2018 | 30 pages | ID: H1B464C4955EN
VPAResearch

Abstracts

Human Parainfluenza Virus 3 (HPIV-3) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline products.

DISEASE OVERVIEW

Human Parainfluenza Virus 3 (HPIV-3) Infections is one of the four types of Parainfluenza that infect respiratory system of an individual. It is often associated with pneumonia and bronchiolitis, bronchitis. With limited or no treatment, the infected person recovers while persons with poor immunity systems are likely to develop fatal complications. Symptoms include running nose, chest pain and breathe related issues. Infants and young children are the most affected group. Unlike Flu that occurs in winter, parainfluenza infections can occur throughout the year.

As no vaccines or antiviral treatment options exist for treatment of HPIV 3 infections, several companies are working on HPIV-3 treatment. Currently, 3-V Biosciences, Inc., Amarillo Biosciences Inc, Ansun Biopharma Inc and Moderna Therapeutics Inc are actively participating in drug development for Human Parainfluenza Virus 3 (HPIV-3) Infections.

REPORT DESCRIPTION

The Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline guide presents complete overview of drugs currently being developed for Human Parainfluenza Virus 3 (HPIV-3) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Human Parainfluenza Virus 3 (HPIV-3) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Human Parainfluenza Virus 3 (HPIV-3) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Human Parainfluenza Virus 3 (HPIV-3) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF HUMAN PARAINFLUENZA VIRUS 3 (HPIV-3) INFECTION PIPELINE REPORT INCLUDES

• Panorama of Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline include-
  Number of Companies with Human Parainfluenza Virus 3 (HPIV-3) Infection projects in pre-clinical Development-
  Number of Companies with Human Parainfluenza Virus 3 (HPIV-3) Infection projects in Clinical Development-
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Companies based in Americas
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Companies based in Europe
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Companies based in Asia Pacific
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Agents in Clinical Development stage
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs-
  Small molecules among the Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline agents

II. INSIGHTS INTO HUMAN PARAINFLUENZA VIRUS 3 (HPIV-3) INFECTION PIPELINE

1. Disease Overview
  Introduction to Human Parainfluenza Virus 3 (HPIV-3) Infection
  Symptoms and Causes of Human Parainfluenza Virus 3 (HPIV-3) Infection
  Treatment or Prevention Options for Human Parainfluenza Virus 3 (HPIV-3) Infection
  Other Details
2. Phase wise Pipeline Compounds
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline- Phase 1 stage Drugs
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline- Phase 2 stage Drugs
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline- Phase 3 stage Drugs
  Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline Compounds
4. Human Parainfluenza Virus 3 (HPIV-3) Infection Pipeline by Mechanism of Action

III. HUMAN PARAINFLUENZA VIRUS 3 (HPIV-3) INFECTION PIPELINE COMPOUND DETAILS

TVB-3567
IFN?A
Paradase
mRNA-1653
Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co-Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. HUMAN PARAINFLUENZA VIRUS 3 (HPIV-3) INFECTION PIPELINE COMPANY BRIEFS

3-V Biosciences Inc
Amarillo Biosciences Inc
Ansun Biopharma Inc
Moderna Therapeutics Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HUMAN PARAINFLUENZA VIRUS 3 (HPIV-3) INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability